Interestingly, tumor-cell expression of FLT1 has been reported in ovarian, pancreatic, and prostate tumors (Boocock et al, 1995; Tsourlakis et al, 2015; Wey et al, 2005), suggesting that FLT1 signaling could potentially drive PARPi resistance in these cancers as well. This evidence concerns the gene FLT1 and prostate neoplasm.